Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/913"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"ABILIFY activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D2 receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma. The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively. Steady-state concentrations are attained within 14 days of dosing for both active moieties."
|
| dc:creator | |
| dc:date |
"04/29/2009 19:25:40"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ aripiprazole_has_metabolite_dehydro-aripiprazole, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1963 }